Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2173-2176

  Spangler, Sheila K ^a   Lin, Gengrong ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFPODOXIME; CEFTRIAXONE; CLARITHROMYCIN; IMIPENEM; PENICILLIN G; SANFETRINEM;

ANTIBIOTIC THERAPY; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0030753432     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2173     Document Type: Article

References (25)

1. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
2. Barry, A. L., M. A. Pfaller, P. C. Fuchs, and R. R. Packer. 1994. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob. Agents Chemother. 38:2419-2425.
3. Block, S., C. J. Harrison, J. A. Hedrick, R. D. Tyler, R. A. Smith, E. Keegan, and S. A. Chartrand. 1995. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr. Infect. Dis. J. 14:751-759.
4. Breiman, R. F., J. C. Butler, F. C. Tenover, J. A. Elliott, and R. R. Facklam. 1994. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835.
5. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
6. Di Modugno, E., I. Erbetti, L. Ferrari, G. Galassi, S. M. Hammond, and L. Xerri. 1994. In vitro activity of the tribactam GV 104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrob. Agents Chemother. 38:2362-2368.
7. Doern, G. V., A. Brueggemann, H. P. Holley, and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40: 1208-1213.
8. Efthymiopoulos, C., A. Capriati, P. Barrington, J. Patel, E. V. B. Shenoy, and A. Bye. 1994. Pharmacokinetics of GV 104326, a novel tribactam antibiotic, following single intravenous and oral (as its prodrug GV 118819X) administration in man, abstr. F82, p. 129. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Friedland, I. R., and G. H. McCracken, Jr. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
10. Hecht, D. W., and L. Lederer. 1995. In vitro activity of GV 104326 compared with six other antibiotics against anaerobic bacteria, abstr. F137, p. 137. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Jacobs, M. R. 1992. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 15:119-127.
12. Kikuchi, K., T. Enari, S. Minami, K. Haruki, Y. Shibata, H. Hasegawa, J. Katahira, K. Totsuka, and K. Shimizu. 1994. Postantibiotic effects and postantibiotic sub-MIC effects of benzylpenicillin on viridans streptococci isolated from patients with infective endocarditis. J. Antimicrob. Chemother. 34:687-696.
13. Liñares, J., T. Alonso, J. L. Pérez, J. Ayats, M. A. Domínguez, R. Pallarés, and R. Martín. 1992. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. J. Antimicrob. Chemother. 30: 279-288.
14. Liñares, J., R. Pallares, T. Alonso, J. L. Perez, J. Ayats, F. Gudiol, P. F. Viladrich, and R. Martin. 1992. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge hospital, Barcelona, Spain (1979-1990). Clin. Infect. Dis. 15:99-105.
15. National Committee for Clinical Laboratory Standards. 1996. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS publication no. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Nelson, C. T., E. O. Mason, Jr., and S. L. Kaplan. 1994. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr. Infect. Dis. J. 13:585-589.
17. Odenholt-Tornqvist, I. 1993. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J. Antimicrob. Chemother. 31:881-892.
18. Odenholt-Tornqvist, I., E. Löwdin, and O. Cars. 1991. Pharmacodynamic effects of subinhibitory concentrations of β-lactam antibiotics in vivo. Antimicrob. Agents Chemother. 35:1834-1839.
19. Odenholt-Tornqvist, I., E. Löwdin, and O. Cars. 1992. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob. Agents Chemother. 36:1852-1858.
20. Oshida, T., T. Onta, N. Nakanishi, T. Matsushita, and T. Yamaguchi. 1990. Activity of sub-minimal inhibitory concentrations of aspoxicillin in prolonging the postantibiotic effect against Staphylococcus aureus. J. Antimicrob. Chemother. 26:29-38.
21. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35:883-888.
22. Singh, K. V., T. M. Coque, and B. E. Murray. 1995. In vitro activity of Glaxo's GV-104326 against gram-positive organisms, abstr. F136, p. 136. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob. Agents Chemother. 38:2902-2904.
24. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1997. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob. Agents Chemother. 41:148-155.
25. Spangler, S. K., M. R. Jacobs, G. A. Pankuch, and P. C. Appelbaum. 1993. Susceptibility of 170 penicillin-susceptible and -resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J. Antimicrob. Chemother. 31:273-280.